Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 981-986

  Yang, Yiling ^a   Shao, Naiyuan ^a   Luo, Guanghua ^a   Li, Lu ^a   Zheng, Lu ^a   Nilsson Ehle, Peter ^b   Xu, Ning ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Glioma; Mutation; PTEN

Indexed keywords

COMPLEMENTARY DNA; DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ADULT; AGED; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CODON, NONSENSE; FEMALE; GENOTYPE; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; NEOPLASM STAGING; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE;

EID: 77951063125     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wrensch M, Minn Y, Chew T, Bondy M and Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4: 278-299, 2002.
2. Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D and Hulsebos TJ: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79: 159-165, 1998.
3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
4. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
5. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R and Tonks NK: P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052-9057, 1997.
6. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998.
7. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD and Bigner SH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187-4190, 1997.
8. Kitange GJ, Templeton KL and Jenkins RB: Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 15: 197-203, 2003.
9. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P and Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest 66: 469-475, 2006.
10. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
11. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S and Rushing EJ: The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 21: 165-177, 2008.
12. Burnet NG, Lynch AG, Jefferies SJ, Price SJ, Jones PH, Antoun NM, Xuereb JH and Pohl U: High-grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother Oncol 85: 371-378, 2007.
13. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG and Louis DN: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159: 359-367, 2001.
14. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC and Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001.
15. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, Sanson M, Delattre JY, Thomas G and Hamelin R: Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 84: 150-154, 1999.
16. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G and Schlegel U: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 48: 89-94, 2000.
17. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK and Steck PA: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 4: 2447-2454, 1998.
18. Tada K, Shiraishi S, Kamiryo T, Nakamura H, Hirano H, Kuratsu J, Kochi M, Saya H and Ushio Y: Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 95: 651-659, 2001.